News and Press Releases
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD 2025 Conference
Data show positive impact of small molecule GAL-201 on Aβ-induced toxicity, caused by various Aβ isoforms: beneficial effects on synaptic plasticity and neuroinflammation 24 March 2025 -- Maryland, US and...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
19 March 2025 -- Dublin, Ireland & New Jersey, US -- Amarin Corporation plc today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
HEALEY ALS Platform Trial Preparation Shows Positive Respiratory Outcome of NUZ-001
Updates to HEALEY ALS Platform Trial Master Protocol have been made to enhance the potential of establishing a clinically meaningful outcome for patients, including: Treatment period extended from 24 to...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
Level 4, 96-100 Albert Road South Melbourne, VIC 3205 Australia
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
First and only EZH2 inhibitor approved by the NMPA HUTCHMED’s fourth product, and its first approval in hematological malignancies. 21 March 2025 -- Hong Kong, Shanghai & New Jersey, US...
Category:
Posted: March 21, 2025
FLAMOD against respiratory infections: phase I clinical trial of innovative new drug begins
20 March 2025 -- Lausanne, Switzerland -- A phase I clinical trial for a groundbreaking therapeutic innovation against respiratory infections has begun at the Clinical Investigation Centre of the Academic...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 20, 2025
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front....
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025
Pistoia Alliance Launches Initiative to Assess Sustainability of Digital vs. Traditional Clinical Trial Approaches
New initiative will collect pharma and CRO data to refine industry carbon measurement of technologies like remote monitoring and eConsent, informing more sustainable trial design 20 March 2025, Massachusetts, US...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025
Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases
DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases Unique mechanism of action with potential to directly impact inflammation,...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France
Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience with Investment in Click Therapeutics for Digital Therapeutics beyond Clinical Trials
This investment will improve the healthcare experience for patients, reinforcing Dassault Systèmes’ role in the industry’s transformation Click Therapeutics will gain access to Dassault Systèmes’ global presence and expertise to...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: March 19, 2025
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
19 March 2025 -- Hong Kong, Shanghai & New Jersey, US -- HUTCHMED (China) Limited and Innovent Biologics, Inc, today jointly announce that the FRUSICA-2 Phase II/III clinical trial evaluating...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 19, 2025
Leading Academic and Manufacturing Organizations Join Ori Biotech’s Preferred Partner Network to Accelerate the Commercialization of Cell and Gene Therapies
Preferred Partner Network (PPN) members will become Centers of Excellence for the IRO platform combining best-in-class technology with industry-leading development and manufacturing capabilities 18 March 2025 -- Pennsylvania, US and...
Category: Biotechnology, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: March 18, 2025
MedExecWomen Hosts 6th Annual Conference to Discuss Future of Medtech Industry
18 March 2025 -- Massachusetts, US -- MedExecWomen, a non-profit organization focused on empowering executive women in medtech to accelerate the positive impact of medical devices, diagnostics, drug delivery, and...
Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: March 18, 2025
